→ PORTFOLIO UPDATE & REFLECTIONS:
Here’s what have changed:
I used the recent volatility to take some profit and consolidate around my highest conviction names.
LONG-TERM PORTFOLIO:
$IREN – 24.2%
$CIFR – 22.2%
$TE – 16.2%
$ONDS – 14.1%
$RKLB – 14.1%
$OSS – 9.1%
SHORT-TERM PORTFOLIO:
$IBRX – 100%
What this tells you:
I’m backing the truck up on AI infrastructure plays; $IREN, $TE, $ONDS, $OSS.
These are convictions that’s only getting stronger.
Why $IREN & $CIFR are now 46% of my portfolio:
> The Microsoft deal didn’t change.
> The hyperscaler arms race didn’t stop.
> Power infrastructure remains the bottleneck everyone’s fighting over.
$IREN controls 4.6GW now. $CIFR 3GW.
Both are scaling and sitting on secured power, and deals.
The drawdown? That was the market giving you a gift.
Why I started a new position in $RKLB:
Space infrastructure isn’t slowing down. It’s accelerating. I’ve been watching $RKLB for a while now. And the dip was a gift.
Rocket Lab is the only pure-play orbital launch company trading at a reasonable valuation (in the growth sector) with PROVEN execution.
It’s the ONLY competitor to @spacex, and market doesn’t like monopoly.
Electron launches. Neutron coming. Defense contracts stacking. The setup is asymmetric.
Why I added to my position in $TE:
$TE owns and operates a 5GW solar With first phase 2.1GW online by end 2026.
AI data centers accelerate power demand. Solar scales rapidly to address grid constraints.
This isn’t complicated. Demand is structural. Supply is constrained.
$TE owns the picks and shovels.
Defense Exposure — $ONDS & $OSS at 23.2% Combined:
NATO spending isn’t reversing. Defense autonomy isn’t optional anymore. These companies own bottleneck technologies in programs that compound for decades.
$ONDS: Raised 2026 guidance by 25%. $65M backlog up 180% in 60 days. Trading below analyst target.
$OSS: Brings high-performance AI to denied, contested, or austere environments where conventional setups cannot operate or introduce lethal latency. No debt.
Watchlist now:
$ASTS – Still on the watchlist. Conviction remains. But execution delays is a risks. Sold and took profit recently.
$KRKNF – Monitoring closely. The Anduril thesis is intact but position sizing matters here. Sold recently.
$NBIS – High conviction but fully allocated for now. Would add on meaningful dips. Sold recently.
$ZETA – Back on the radar. Took profit earlier but watching for potential re-entry if the right setup allows.
$RDW – Watching.
$SATL – Watching. Early-stage conviction building.
$PGY – Under review.
Short-Term Play: $IBRX at 100%
This is the asymmetric bet.
Biotech with binary catalyst potential. High risk, high reward.
I’m watching this daily and will adjust fast if thesis breaks.
My approach right now:
> Market volatility doesn’t change fundamentals.
> AI infrastructure spending is going from $200B to $500B+.
> Defense budgets are locked in for years.
> Energy demand is structural.
> The companies I own control bottlenecks in these trends.
> Drawdowns are buying opportunities when conviction is high.
I used this one to concentrate around my strongest theses.
Bottom line, this portfolio is built around:
→ AI/energy infrastructure bottlenecks
→ Defense tech with sole-source positioning
→ Space infrastructure with proven execution
→ One asymmetric biotech swing
Every position is sized by conviction.
The drawdown strengthened my hand.
My conviction didn’t drop. It increased.
Adding on potential dips.
Note: This is not financial advice.
Show More
